ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Northern Trust Corp

Northern Trust Corp increased its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 5.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 478,153 shares of the company's stock after acquiring an additional 25,773 shares during the period. Northern Trust Corp owned about 0.49% of ARS Pharmaceuticals worth $5,045,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in shares of ARS Pharmaceuticals in the 4th quarter worth $73,000. Compass Capital Corp MA ADV purchased a new position in ARS Pharmaceuticals during the 4th quarter worth $106,000. Teacher Retirement System of Texas purchased a new position in ARS Pharmaceuticals during the 4th quarter worth $122,000. Amica Mutual Insurance Co. purchased a new position in ARS Pharmaceuticals during the 4th quarter worth $151,000. Finally, PEAK6 LLC purchased a new position in ARS Pharmaceuticals during the 4th quarter worth $162,000. 68.16% of the stock is owned by institutional investors.

ARS Pharmaceuticals Stock Down 2.4%

Shares of SPRY stock traded down $0.36 on Tuesday, hitting $14.62. The company had a trading volume of 1,231,541 shares, compared to its average volume of 1,257,625. The firm has a market cap of $1.44 billion, a P/E ratio of -28.67 and a beta of 0.84. The company has a 50-day moving average price of $13.68 and a 200-day moving average price of $12.83. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The company had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million. Equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

Analyst Ratings Changes

SPRY has been the topic of several research analyst reports. Oppenheimer initiated coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They set an "outperform" rating and a $40.00 target price on the stock. Wall Street Zen cut ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ARS Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $31.00.

Insider Activity

In other ARS Pharmaceuticals news, CFO Kathleen D. Scott sold 50,000 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total value of $705,000.00. Following the completion of the sale, the chief financial officer now directly owns 7,424 shares in the company, valued at $104,678.40. This represents a 87.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $1,451,862.90. Following the completion of the sale, the insider now owns 89,613 shares of the company's stock, valued at approximately $1,263,543.30. The trade was a 53.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 382,571 shares of company stock valued at $5,177,904 in the last quarter. 33.50% of the stock is currently owned by company insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.